Healthcare | medical

Zevendael is supporting the activities of an USA based company involved in the commercialization of a first-in-class Viral Host Inhibitor for the treatment of HIV/AIDS and platform for the treatment of other Viral and Non-Viral Infections. The Drug’s low cost, high efficacy, non-toxic approach, low side-effect profile, reduced resistance issues and simplicity offer many attractive competitive advantages when compared to the most widely accepted current HIV/AIDS treatments. The results of in vitro testing and small-scale clinic testing on the Drug are very promising and the protocol for extended clinical testing is complete.